Background: Acute acalculous cholecystitis (AAC) is a rare complication of systemic lupus erythematosus (SLE) but should be recognized Objectives: The aim was to describe clinical, biological and radiological features of AAC in SLE patients. Methods: We report four cases of AAC complicating SLE among 246 patients. Results: Case 1: A 37-year-old woman with one year history of arthralgia and Raynaud's phenomenon was admitted for fever, cutaneous lesions, nausea and abdominal pain. The right upper quadrant of the abdomen was tender and we noted oral ulcerations and wrist synovitis. Laboratory data showed lymphopenia, hemolytic anemia and an inflammatory syndrome. There was no cholestasis or cytolysis. Antinuclear antibodies (ANA), anti-nucleosome, anti-Sm and antiribosome antibodies were positive. Abdominal sonography revealed ascites and gallbladder wall was thick and irregular. The diagnosis of AAC complicating a SLE was made and patient was treated with antibiotics and corticosteroids. Two weeks later, she was asymptomatic and abdominal sonography was normal. Case 2: A 32-year-old woman had SLE with arthralgia, cutaneous manifestations, hematological involvements and pulmonary hypertension; she was treated with corticosteroids and cyclophosphamide. Six month later, at time of the second pulse of cyclophosphamide, she presented with jaundice and tender hepatomegaly without abdominal pain. Liver enzymes rates were normal except bilirubin which was high at 47 UI. Her abdominal sonography showed gallbladder wall thickness without bile ducts enlargement or gallstones. Patient was continued on steroids and cyclophosphamide but she died because of heart failure. Case 3: A 40-year-old patient with 12-year-history of SLE was admitted for fever and dyspnea. On physical examination, there was tenderness on right upper quadrant of her abdomen. Cholestasis and cytolysis were found. Abdominal sonography showed a striated and thick gallbladder wall (17 mm). Computer tomography confirmed the gallbladder wall thickness and note pericholecystic edema. Patient was also diagnosed with myocarditis and seritis. A new SLE relapse was obvious and she was treated with prednisone 1 mg/kg/day and azathioprine. The outcome was good and she still is asymptomatic. Case 4: A 56-year-old-woman was admitted with abdominal pain and fever, limbs paresthesia. Abdominal examination was normal. Biological data showed anemia, thrombopenia and cholestasis. ANA, anti-DNA and anti-Sm were positive. Abdominal sonography showed gallbladder wall thickness and pericholecystic edema. SLE diagnosis with peripheral neuropathy, lupus nephritis, hematological manifestations and ACC was made. Patient was given corticosteroids and cyclophosphamide with good outcome. Conclusions: Only few cases of AAC complicating SLE are reported. Cholecystitis can be an initial manifestation of SLE and reveal the disease or can occur at any time of the disease course. ACC is always associated to other disease manifestations. Patients present with abdominal pain, vomiting and fever. Ultrasonography and computed tomography confirm the diagnosis. The outcome is good with steroids. Sometimes patients are given antibiotics and/or underwent cholecystectomy because of infectious cholecystisis suspicion. None of our patients had surgery. Background: TNF-like WEAK inducer of apoptosis (TWEAK) is able to increase the expression of various molecules involved in the inflammatory response with relevant effects also in angiogenesis. The pathological functions of TWEAK are primarily attributed to its ability to induce the expression of several proinflammatory cytokines, chemokines and cell adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1) (1). Some previous studies (most of them in Caucasic, Afro-American and Asiatic cohorts) have demonstrated clinical utility of VCAM-1 and TWEAK as biomarkers in patients with systemic lupus erythematosus SLE (2). Objectives: To evaluate the diagnostic value of urinary VCAM-1 and TWEAK in a cohort of Latin-American patients with SLE. Methods: Patients meeting the revised ACR criteria for SLE were recruited from 2 different centers at Medellín and Baranquilla, Colombia. Urinary levels of VCAM-1 (uVCAM-1) and TWEAK (uTWEAK) were measured using an ELISA kit (R&D system, USA). SLE activity was measured with SLEDAI. Inactive LN was defined by the presence of: 24 hours proteinuria ≤500 mg/dl, inactive urine sediments and stable serum creatinine. Mann-Whitney tests were used to compare data and Spearman's rank correlations were used to examine associations.
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Results: One hundred and fifty eight SLE patients were recruited (89% female) with median age of 32.8±12.1 years and median disease duration of 7.27±6.6 years. Mestizo (77%) and African Latin-American patients (20%) were majority. Mean SLEDAI score was 8.5±8.7. One hundred and four patients (64%) had lupus nephritis (LN). 76 out of 104 patients had biopsy proven LN, in 62% of cases with proliferative forms. uVCAM-1 and uTWEAK were significantly higher in patients with LN than without LN. At the same time, uVCAM-1 and uTWEAK were significantly higher in patients with active vs inactive LN (Figure) . uVCAM-1 (581±1197 vs 189±256 ng/ml, p<0.001) and uTWEAK levels (3202±3778 vs 1123±1873 pg/ml, p=0.038) were significantly higher in patients with Class V LN in comparison with other LN classes. uVCAM-1 and uTWEAK levels had a mild positive correlation with SLEDAI (r=0.22 and r=0.16, respectively). In addition, uTWEAK correlated with 24 hours proteinuria (r=0.28). No significant correlation was found between uVCAM-1 and uTWEAK. Conclusions: uVCAM-1 and uTWEAK are useful biomarkers in Latin-American patients with SLE for the identification of patients with LN and active LN. In addition, urinary levels of VCAM-1 and TWEAK were significantly more elevated in patient with membranous LN. Background: Patients with active systemic lupus erythematosus (SLE) are considered to have raised erythrocyte sedimentation rate (ESR) rather than raised C-reactive protein (CRP). Yet published evidence is low for this statement. DsDNA-antibodies, C3 complement, ferritin and proteinuria are also commonly applied to assess SLE. Objectives: Firstly, to assess how ESR correlates with above mentioned laboratory parameters: in general, in the presence of clinical activity and/or infection or in the absence of both. Secondly, to determine if these parameters are associated with disease flare or infections. Methods: A retrospective analysis of patients of a tertiary referral centre with SLE who underwent inpatient treatment between 2006 and 2015. Data on laboratory parameters, infection and disease flare, judged by the treating physician, were extracted. Patients were divided in four SLE groups: flare only (n=147), infection only (n=48), both (n=23), and neither infection nor flare (n=153). ESR was correlated to CRP, ferritin, proteinuria, C3-reduction and raised dsDNA-antibodies for the whole cohort and within each SLE group. Further, the association between all laboratory parameters and a) disease activity with and without infection, b) the presence of infection with and without disease activity, was tested. Results: We identified 203 SLE patients, 26 males, with a total of 371 visits. Mean age was 45.6 years (SD± 16.5 years). Table 1 (top part) shows the correlation coefficients of ESR with the other laboratory parameters. ESR correlated moderately with CRP amongst all groups (r=0.47-0.58); weakly with ferritin in the general and the flare group (r=0.26); and very weakly with C3-reduction and raised dsDNA-antibodies (r<0.2) in each group. Concerning proteinuria, the correlation was weak for all, for flaring and for silent patients (r=0.22 -0.35), moderate for patients with both infection and activity (r=0.56). There was no correlation in infected patients (r <0.06). Table 1 (bottom part) displays the p-values for the association of parameters with disease activity or infection, respectively. ESR, reduction of C3, proteinuria and raised dsDNA-antibodies were all associated with disease activity in the whole cohort and in the non-infected group; CRP only in non-infected patients. In the infected group, raised dsDNA-antibodies and proteinuria were the only parameters showing significant relation to disease activity. ESR and CRP were significantly associated with infections when looking at all or at inactive patients, but not in active patients. Background: Organ damage in patients with systemic lupus erythematosus (SLE) occurs as the consequence of the disease itself, administered therapy, primarily corticosteroid and cytostatic, as well as the accompanying diseases and complications. Objectives: Our aim in this paper was to examine the degree of irreversible organ changes in SLE patients using the SLICC/ACR Damage Index (SDI) and to establish the correlation of organ damage with disease activity, quality of life, and severity of fatigue, as well as with the immunological parameters -anti-dsDNA antibodies, anti-nucleosome, anti-C1q antibodies, and MCP1 in the serum and urine. Methods: The study involved 83 SLE patients (77 women and 6 men), aged 45.8±9.2 years on the average, with average disease duration of 10.6±7.9 years, hospitalized at the Clinic of Rheumatology of the "Niška Banja" Institute, in whom the diagnosis was made based on the revised 1997 ACR criteria. The disease activity was evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and a physician's global assessment. The degree of organ damage was evaluated using the SDI. The quality of life was assessed based on The Medical Outcome Survey Short Form 36 (SF-36), and the severity of fatigue was measured using the Fatigue Severity Scale (FSS). The level of antibodies was determined using the ELISA test, and serum and urine MCP1 with the sandwich enzyme immunosorbent assay method according to the manufacturer's instructions (R&D Systems, Inc. Minneapolis, USA).
Conclusions

Results:
The mean value of organ damage index in all SLE patients was 1.8±2.0 (median 1, min 0, max 9). Twenty-five (30.1%) patients did not have any organ damage (SDI=0); 21 (25.3%) had SDI=1; SDI=2 or 3 was found in 20 patients (24.1%), and 17 patients (20.5%) had SDI≥4. Neuropsychic and musculoskeletal changes were the most common organ damage manifestations, present in 23 (27.7%) of patients. In 21 patients (25.3%), cardiovascular changes were seen, and ocular lesions in 14 patients (16.9%). Renal and pulmonary changes were found in 13 patients (15.7%), cutaneous changes in 3 patients (3.6%), and gastrointestinal changes in 2 patients (2.4%). In 5 cases (6.0%) malignancies were detected, and diabetes mellitus in 2 patients (2.4%). A statistically significant positive correlation of SDI was established with age (r=0,348, p=0,001), disease duration (r=0,412, p<0,001), SLEDAI (r=0, 359, p=0, 001) , global physician's assessment (r=0,357, p=0,001) and fatigue (r=0,296, p=0,007), and a negative correlation with quality of life (r=-0,386, p<0,001). There were no correlations of SDI with the level of anti-dsDNA, anti-nucleosome, anti-C1q antibodies, nor with serum and urine MCP1 levels. Conclusions: Musculoskeletal, neuropsychic, and cardiovascular changes were the ones most commonly seen. Organ damage positively correlated with age and disease duration, a higher disease activity, poorer quality of life, and more severe fatigue. Background: The improved survival of patients with Systemic Lupus Erythematosus (SLE) over the past decades highlighted the problem of co-morbidity (several different chronic pathologies presence) in SLE patients because many of them reach the age when the burden of concomitant diseases could increase and become ordinary. Objectives: To evaluate the frequency of concomitant diseases and to estimate the total co-morbidity status in SLE patients. Methods: The retrospective study of co-morbidity in SLE patients was conducted on the database of Byelorussian Republican Rheumatologic Center. It included 212 patients: 192 women and 20 men at the age of 16.1 to 68.3 (mean ± SD: 33.2±12.3 years) at the baseline (first visit). The diagnosis of SLE was in conformance with 1997 ACR modified classification criteria for SLE [1] . The comprehensive assessment of patient co-morbidities was performed by KaplanFeinstein co-morbidity index (KFI) [2] which includes twelve pathology categories: arterial hypertension (HT), heart disease (HD) presence, nervous system (ND) involvement, respiratory system (RD) pathology, vascular (VD), kidney (KD), liver (LD) gastrointestinal (GID) and musculoskeletal (MSD) diseases, other pathology (OD), malignancies and alcoholism. A co-morbidity score of 1 indicates low level of co-morbidity, 2 -moderate and 3 -high level of co-morbidity for corresponding pathology. The possible grade of co-morbidity is calculated as a sum score for all categories and varies from 0 to 36 points. Results: KFI in SLE patients at the first visit varied from 0 to 7 points (Me: 2; 25-75% range: 0-3) and had minor differences in age and sex groups (NS, Fisher's exact test). One-third of patients (n=68) had no co-morbidities. One of the most common pathology was HT which was diagnosed in 39 patients (18.4%, 95% CI 5.6-26.7%): 34 women and 5 men (p=0.591, NS, Fisher's exact test). Over the 13-year follow-up period the frequency of HT dramatically increased to 52.9% (95% CI 37.0-68.0%) i.e. 2.9 times vs baseline (p<0,001). Prognostic odds ratios (pOR) of HT were 7.6 (95% CI 3.1-18.2) and 3.2 (1.4-7.6) for lupus nephritis presence and signs of glucucorticoid disease ("cushingoid"), correspondingly. Other common co-morbidities were GID and HD. Coronary HD and congestive heart failure were revealed in 43 (20.3%) patients. GID were registered in 44 (20.8%) patients, among them 9 (4.2%) patients had gastric/duodenal ulcer. VD, ND and RD were revealed in 7 (3.3%) patients for each category, KD and LD frequency was 6 (2.8%) for both pathology. MSD were registered in 8 (3.8%) and OD, including different infections, anemia, diabetes etc. were registered in 39 (18.4%) patients. There were no cases of malignancies or alcoholism in our patients. Conclusions: Total co-morbidity status revealed in SLE patients at baseline varied up to the 20 percent of the maximal possible level for all age and sex groups. Arterial hypertension was one of the most common pathology which demonstrated significant and predictable growth over the 13-year follow-up period. 
